Track 13: Vaccine Safety & Efficacy


Antibody adequacy alludes to the capacity of immunizations to achieve the proposed useful consequences for inoculated people in a characterized populace under perfect states of utilization. The potential advantages of a successful immunization – for example advancement of wellbeing and prosperity, and assurance from ailment and its physical, mental and financial outcomes must be weighed against the potential danger of an antagonistic occasion following vaccination (AEFI) with that immunization. Antibody related hazard is the likelihood of an unfavorable or undesirable result happening, and the seriousness of the subsequent mischief to the wellbeing of inoculated people in a characterized populace following vaccination with an immunization under perfect states of utilization.


  • Influenza Vaccines
  • Measles Vaccines

Related Conference of Track 13: Vaccine Safety & Efficacy

May 30-31, 2024

World congress on Immunology and Virology Diseases

Vienna, Austria
August 01-02, 2024

44th Global Summit and Expo on Vaccines & Immunology

Montreal, Canada
September 09-10, 2024

4th International Conference on Vaccine Research

Madrid, Spain
September 09-10, 2024

7th International Conference on Vaccines and Immunology

Madrid, Spain
November 28-29, 2024

6th World Congress on Vaccine and Immunology

Paris, France

Track 13: Vaccine Safety & Efficacy Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in